Answers are grounded in this paper and cite their sources.
Background: Neurological and cardiotoxicity associated with bupivacaine led to research of alternatives for subarachnoid block (SAB) with comparable efficacy and better safety. This study aimed to compare the anesthetic efficacy and safety of 0.75% hyperbaric ropivacaine with 0.5% hyperbaric bupivacaine in SAB. Materials and Methods: A randomized, double-blinded study was conducted on 60 American Society of Anesthesiologists I–III patients undergoing lower limb surgeries. Patients were divided into two equal groups of 30 each. Group R received 2.5 ml of 0.75% hyperbaric ropivacaine with 25 µg fentanyl, and Group B received 2.5 ml of 0.5% hyperbaric bupivacaine with 25 µg fentanyl. Onset of sensory and motor block, maximum sensory level and time to achieve it, duration of complete motor block, two-segment sensory regression, duration of analgesia, and episodes of hypotension were observed. Results: Difference in onset of sensory and motor block, maximum sensory level and time to achieve it, and duration of motor block were statistically insignificant between the two groups ( P > 0.05). Time to two-segment sensory regression was significantly longer in Group R (99.27 ± 11.79 min) than Group B (85.17 ± 19.19 min) ( P = 0.001). The duration of analgesia was significantly lower in the Group R (264.33 ± 46.72 min) than Group B (300.73 ± 62.85 min) ( P = 0.013). More episodes of hypotension were observed in Group B ( P = 0.033). Conclusion: Intrathecal hyperbaric ropivacaine 0.75% offers a reasonable degree of sensory and motor block for lower limb surgeries and is thus a comparable alternative to bupivacaine with lower hypotensive incidence.
No takes yet. Share an insight, caveat, or question.
Bhanot et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: